Kwang Sup So1, Jin Kyung Rho2, Yun Jung Choi3, Seon Ye Kim3, Chang Min Choi4, Young Jin Chun5, Jae Cheol Lee6. 1. Department of Pulmonary and Critical Care Medicine, University of Ulsan, Seoul, Republic of Korea College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea. 2. Department of Pulmonary and Critical Care Medicine, University of Ulsan, Seoul, Republic of Korea Asan Institute for Life Sciences, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Republic of Korea. 3. Department of Pulmonary and Critical Care Medicine, University of Ulsan, Seoul, Republic of Korea. 4. Department of Pulmonary and Critical Care Medicine, University of Ulsan, Seoul, Republic of Korea Department of Oncology, University of Ulsan, Seoul, Republic of Korea. 5. College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea jclee@amc.seoul.kr yjchun@cau.ac.kr. 6. Department of Oncology, University of Ulsan, Seoul, Republic of Korea jclee@amc.seoul.kr yjchun@cau.ac.kr.
Abstract
AIM: The response to chemotherapeutic drugs in non-small cell lung cancer (NSCLC) is unsatisfactory, leading to poor outcomes. This study the aimed to investigates anticancer effects of CX-4945, a potent casein kinase II (CK2) inhibitor, in chemorefractory NSCLC cells. MATERIALS AND METHODS: Cell proliferation and apoptosis assay were carried-out by annexin V-FITC and FACScan after drug treatment with paclitaxel, cisplatin and CX-4945. AKT/mTOR and CK2α signals were measured by western blotting. Treatment was carried-out using siRNA to inhibit CK2α. RESULTS: Paclitaxel, and cisplatin effectively inhibited cell proliferation and induced apoptosis in A549 cells, while not in H1299, Calu-1 and H358 cells. In these chemorefractory cell lines, AKT signalling was maintained despite drug treatment. However, CX-4945 suppressed cell growth, with cell-cycle arrest at G2/M phase and induced apoptosis with an increase of cleaved caspase-3 and PARP1 in a dose-dependent manner. Accordingly, AKT and its downstream signals such as mTOR and p70S6K were down-regulated by CX-4945. Transfection of CK2α siRNA had similar effects to CX-4945 treatment on cell proliferation and apoptosis. CONCLUSION: CX-4945 shows a promising anticancer action through down-regulation of AKT/mTOR signals, suggesting its possible application for treatment of chemorefractory lung cancer. Copyright
AIM: The response to chemotherapeutic drugs in non-small cell lung cancer (NSCLC) is unsatisfactory, leading to poor outcomes. This study the aimed to investigates anticancer effects of CX-4945, a potent casein kinase II (CK2) inhibitor, in chemorefractory NSCLC cells. MATERIALS AND METHODS: Cell proliferation and apoptosis assay were carried-out by annexin V-FITC and FACScan after drug treatment with paclitaxel, cisplatin and CX-4945. AKT/mTOR and CK2α signals were measured by western blotting. Treatment was carried-out using siRNA to inhibit CK2α. RESULTS:Paclitaxel, and cisplatin effectively inhibited cell proliferation and induced apoptosis in A549 cells, while not in H1299, Calu-1 and H358 cells. In these chemorefractory cell lines, AKT signalling was maintained despite drug treatment. However, CX-4945 suppressed cell growth, with cell-cycle arrest at G2/M phase and induced apoptosis with an increase of cleaved caspase-3 and PARP1 in a dose-dependent manner. Accordingly, AKT and its downstream signals such as mTOR and p70S6K were down-regulated by CX-4945. Transfection of CK2α siRNA had similar effects to CX-4945 treatment on cell proliferation and apoptosis. CONCLUSION:CX-4945 shows a promising anticancer action through down-regulation of AKT/mTOR signals, suggesting its possible application for treatment of chemorefractory lung cancer. Copyright
Authors: Anna Maria Lustri; Sabina Di Matteo; Alice Fraveto; Daniele Costantini; Alfredo Cantafora; Chiara Napoletano; Maria Consiglia Bragazzi; Felice Giuliante; Agostino M De Rose; Pasquale B Berloco; Gian Luca Grazi; Guido Carpino; Domenico Alvaro Journal: PLoS One Date: 2017-09-05 Impact factor: 3.240
Authors: Janeen H Trembley; Bin Li; Betsy T Kren; Amy A Gravely; Emiro Caicedo-Granados; Mark A Klein; Khalil Ahmed Journal: Biomedicines Date: 2021-05-18
Authors: Eduardo Silva-Pavez; Paulina Villar; César Trigo; Esteban Caamaño; Ignacio Niechi; Pablo Pérez; Juan P Muñoz; Francisco Aguayo; Verónica A Burzio; Manuel Varas-Godoy; Ariel F Castro; María I Colombo; Julio C Tapia Journal: Cell Death Dis Date: 2019-01-25 Impact factor: 8.469